Indo-Bangla Pharmaceuticals Limited (DSE:IBP)
Bangladesh
· Delayed Price · Currency is BDT 13.10
-0.30 (-2.24%)
At close: Mar 5, 2026
DSE:IBP Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jul '22 Jul 1, 2022 | Jul '21 Jul 1, 2021 | 2020 - 2016 |
| Revenue | 198.02 | 184.18 | 176.64 | 374.48 | 484.68 | 782.24 | Upgrade
|
| Revenue Growth (YoY) | 66.30% | 4.27% | -52.83% | -22.74% | -38.04% | -9.68% | Upgrade
|
| Cost of Revenue | 169.1 | 163.15 | 156.79 | 277.92 | 337.75 | 469.3 | Upgrade
|
| Gross Profit | 28.92 | 21.02 | 19.85 | 96.56 | 146.93 | 312.94 | Upgrade
|
| Selling, General & Admin | 48.91 | 45.07 | 43.61 | 67.88 | 111.13 | 139.64 | Upgrade
|
| Other Operating Expenses | 0.02 | 0.02 | - | - | - | - | Upgrade
|
| Operating Expenses | 48.93 | 45.08 | 43.61 | 67.88 | 111.13 | 139.64 | Upgrade
|
| Operating Income | -20 | -24.06 | -23.76 | 28.68 | 35.8 | 173.3 | Upgrade
|
| Interest Expense | -2.02 | -1.87 | -4.4 | -5.23 | -4.88 | -3.81 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.05 | 0.1 | 0.25 | 0.42 | 0.8 | 0.63 | Upgrade
|
| EBT Excluding Unusual Items | -21.98 | -25.83 | -27.91 | 23.87 | 31.72 | 170.11 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | 0.7 | - | -0.77 | Upgrade
|
| Pretax Income | -21.98 | -25.83 | -27.91 | 24.57 | 31.72 | 169.34 | Upgrade
|
| Income Tax Expense | 10.62 | 11 | 13.07 | 16.17 | 6.55 | 34.62 | Upgrade
|
| Net Income | -32.6 | -36.83 | -40.98 | 8.41 | 25.17 | 134.73 | Upgrade
|
| Net Income to Common | -32.6 | -36.83 | -40.98 | 8.41 | 25.17 | 134.73 | Upgrade
|
| Net Income Growth | - | - | - | -66.60% | -81.31% | -13.77% | Upgrade
|
| Shares Outstanding (Basic) | 122 | 116 | 116 | 116 | 116 | 114 | Upgrade
|
| Shares Outstanding (Diluted) | 122 | 116 | 116 | 116 | 116 | 114 | Upgrade
|
| Shares Change (YoY) | 4.74% | - | - | - | 2.17% | - | Upgrade
|
| EPS (Basic) | -0.27 | -0.32 | -0.35 | 0.07 | 0.22 | 1.18 | Upgrade
|
| EPS (Diluted) | -0.27 | -0.32 | -0.35 | 0.07 | 0.22 | 1.18 | Upgrade
|
| EPS Growth | - | - | - | -66.60% | -81.71% | -13.77% | Upgrade
|
| Free Cash Flow | 66.7 | 57.89 | 23.64 | 42.92 | 47.6 | -49.39 | Upgrade
|
| Free Cash Flow Per Share | 0.55 | 0.50 | 0.20 | 0.37 | 0.41 | -0.43 | Upgrade
|
| Dividend Per Share | - | 0.015 | 0.010 | - | 0.100 | 0.400 | Upgrade
|
| Dividend Growth | - | 50.00% | - | - | -75.00% | - | Upgrade
|
| Gross Margin | 14.61% | 11.42% | 11.24% | 25.79% | 30.31% | 40.01% | Upgrade
|
| Operating Margin | -10.10% | -13.06% | -13.45% | 7.66% | 7.39% | 22.15% | Upgrade
|
| Profit Margin | -16.46% | -20.00% | -23.20% | 2.25% | 5.19% | 17.22% | Upgrade
|
| Free Cash Flow Margin | 33.68% | 31.43% | 13.38% | 11.46% | 9.82% | -6.31% | Upgrade
|
| EBITDA | 8.55 | 4.4 | 4.78 | 67.05 | 74.93 | 209.2 | Upgrade
|
| EBITDA Margin | 4.32% | 2.39% | 2.71% | 17.90% | 15.46% | 26.74% | Upgrade
|
| D&A For EBITDA | 28.56 | 28.46 | 28.54 | 38.36 | 39.13 | 35.9 | Upgrade
|
| EBIT | -20 | -24.06 | -23.76 | 28.68 | 35.8 | 173.3 | Upgrade
|
| EBIT Margin | -10.10% | -13.06% | -13.45% | 7.66% | 7.39% | 22.15% | Upgrade
|
| Effective Tax Rate | - | - | - | 65.79% | 20.64% | 20.44% | Upgrade
|
| Advertising Expenses | - | 0.12 | 0.1 | 0.77 | 4.19 | 7.02 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.